文献速递白血病

短亚型Wilms瘤1基因上调HOXA3驱动急性髓系白血病化疗耐药

Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2024-06-12

研究发现急性髓系白血病中短亚型WT1转录本过表达导致细胞生长减慢、CD71表达下降、G1期阻滞和阿糖胞苷耐药,RNA测序显示HOXA3和GATA2在sWT1+/-细胞中特异性上调,过表达HOXA3或GATA2可重现上述效应,HOXA3表达与NPM1突变阴性白血病标本的化疗反应和总生存相关。

要点

  • 短亚型WT1(sWT1+/-)过表达导致CD71下降、G1期阻滞和阿糖胞苷耐药
  • 低CD71表达的原发AML患者细胞对阿糖胞苷耐药,CD71或为化疗生物标志物
  • HOXA3过表达导致对广谱化疗药物耐药,其表达与NPM1突变阴性白血病化疗反应和总生存相关

核心结论

  • WT1以亚型特异性方式调控细胞增殖和药物敏感性,短亚型WT1通过上调HOXA3驱动急性髓系白血病化疗耐药。

研究设计与样本

  • 研究在急性髓系白血病细胞中过表达短亚型WT1转录本(sWT1+/-和sWT1-/-),并通过RNAseq差异表达基因分析及原发AML患者细胞实验进行验证。

主要发现

  • 过表达sWT1+/-和sWT1-/-均导致细胞生长减少,但仅sWT1+/-过表达导致CD71表达下降、G1期阻滞和阿糖胞苷耐药。
  • 低CD71表达的原发AML患者细胞对阿糖胞苷耐药。
  • RNAseq分析显示HOXA3和GATA2在sWT1+/-细胞中特异性上调,CDKN1A在sWT1-/-细胞中上调。
  • 过表达HOXA3或GATA2可重现sWT1+/-的效应,包括细胞生长减少、G1期阻滞、CD71表达下降和阿糖胞苷耐药。
  • HOXA3表达与NPM1突变阴性白血病标本的化疗反应和总生存相关;过表达HOXA3导致对广谱化疗药物耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Upregulation of the Wilms' tumour 1 (WT1) gene is common in acute myeloid leukaemia (AML) and is associated with poor prognosis. WT1 generates 12 primary transcripts through different translation initiation sites and alternative splicing. The short WT1 transcripts express abundantly in primary leukaemia samples. We observed that overexpression of short WT1 transcripts lacking exon 5 with and without the KTS motif (sWT1+/- and sWT1-/-) led to reduced cell growth. However, only sWT1+/- overexpression resulted in decreased CD71 expression, G1 arrest, and cytarabine resistance. Primary AML patient cells with low CD71 expression exhibit resistance to cytarabine, suggesting that CD71 may serve as a potential biomarker for chemotherapy. RNAseq differential expressed gene analysis identified two transcription factors, HOXA3 and GATA2, that are specifically upregulated in sWT1+/- cells, whereas CDKN1A is upregulated in sWT1-/- cells. Overexpression of either HOXA3 or GATA2 reproduced the effects of sWT1+/-, including decreased cell growth, G1 arrest, reduced CD71 expression and cytarabine resistance. HOXA3 expression correlates with chemotherapy response and overall survival in NPM1 mutation-negative leukaemia specimens. Overexpression of HOXA3 leads to drug resistance against a broad spectrum of chemotherapeutic agents. Our results suggest that WT1 regulates cell proliferation and drug sensitivity in an isoform-specific manner.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Allen B, Savoy L, Ryabinin P, et al. Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia. Br J Haematol. 2024. PMID: 38867543. doi:10.1111/bjh.19563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。